ArticleFrontiers in public health2025
Intraocular gases and climate change: a call for sustainable vitreoretinal surgery.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Perfluoropropane (C₃F₈) and sulfur hexafluoride (SF₆) are established agents in vitreoretinal surgery. Their tamponade properties support anatomic success, but both gases have very high global warming potentials and extremely long atmospheric lifetimes. Given the health sector's considerable share of global greenhouse emissions, emissions attributable to intraocular gases constitute a discrete, measurable, and modifiable component of surgical practice. This Perspective synthesizes published evidence on the climate impact of C₃F₈ and SF₆ in routine vitreoretinal care and outlines actions at three levels. First, clinical practice: standardize low-concentration mixtures, match prepared volume to need, improve decanting technique, and consider air tamponade in appropriate indications. Second, implementation systems: training, checklists, and simple process metrics (prepared-to-injected ratios; concentration adherence) to reduce variation and waste. Third, institutional and policy measures: procurement criteria that favor lower GWP options and right sized packaging, guideline updates, audit indicators, and product level carbon disclosure. These steps do not introduce new clinical risk when applied with standard safeguards and may yield cost savings by reducing gas consumption. Because fluorinated intraocular gases are potent, long lived, and tied to modifiable routines, targeted measures in this niche can produce outsized gains for planetary health relative to effort.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.